Vieira J, Huang ML, Koelle DM, Corey L. Transmissible Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) in saliva of men with a history of Kaposi’s sarcoma. J Virol. 1997;71(9):7083–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Koelle DM, Huang ML, Chandran B, Vieira J, Piepkorn M, Corey L. Frequent detection of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) DNA in saliva of human immunodeficiency virus-infected men: clinical and immunologic correlates. J Infect Dis. 1997;176(1):94–102.

Article  CAS  PubMed  Google Scholar 

Minhas V, Wood C. Epidemiology and transmission of Kaposi’s sarcoma-associated herpesvirus. Viruses. 2014;6(11):4178–94.

Article  PubMed  PubMed Central  Google Scholar 

Blackbourn DJ, Lennette ET, Ambroziak J, Mourich DV, Levy JA. Human herpesvirus 8 detection in nasal secretions and saliva. J Infect Dis. 1998;177(1):213–6.

Article  CAS  PubMed  Google Scholar 

Casper C, Redman M, Huang ML, Pauk J, Lampinen TM, Hawes SE, Critchlow CW, Morrow RA, Corey L, Kiviat N, et al. HIV infection and human herpesvirus-8 oral shedding among men who have sex with men. J Acquir Immune Defic Syndr. 2004;35(3):233–8.

Article  PubMed  Google Scholar 

Casper C, Krantz E, Selke S, Kuntz SR, Wang J, Huang ML, Pauk JS, Corey L, Wald A. Frequent and asymptomatic oropharyngeal shedding of human herpesvirus 8 among immunocompetent men. J Infect Dis. 2007;195(1):30–6.

Article  PubMed  Google Scholar 

Gantt S, Casper C. Human herpesvirus 8-associated neoplasms: the roles of viral replication and antiviral treatment. Curr Opin Infect Dis. 2011;24(4):295–301.

Article  PubMed  PubMed Central  Google Scholar 

Casper C, Krantz EM, Corey L, Kuntz SR, Wang J, Selke S, Hamilton S, Huang ML, Wald A. Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial. J Infect Dis. 2008;198(1):23–30.

Article  CAS  PubMed  Google Scholar 

Curran M, Noble S, Valganciclovir. Drugs. 2001;61(8):1145–50. discussion 1151– 1142.

Xiao P, Gumber S, Marzinke MA, Date AA, Hoang T, Hanes J, Ensign LM, Wang L, Rohan L, Fuchs EJ et al. Hypo-Osmolar Formulation of Tenofovir (TFV) Enema promotes uptake and metabolism of TFV in tissues, leading to Prevention of SHIV/SIV infection. Antimicrob Agents Chemother 2018, 62(1).

Carballo-Dieguez A, Giguere R, Lentz C, Dolezal C, Fuchs EJ, Hendrix CW. Rectal Douching Practices Associated with Anal Intercourse: implications for the development of a behaviorally congruent HIV-Prevention rectal microbicide Douche. AIDS Behav. 2019;23(6):1484–93.

Article  PubMed  PubMed Central  Google Scholar 

Kaldor SW, Kalish VJ, Davies JF 2nd, Shetty BV, Fritz JE, Appelt K, Burgess JA, Campanale KM, Chirgadze NY, Clawson DK, et al. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J Med Chem. 1997;40(24):3979–85.

Article  CAS  PubMed  Google Scholar 

Moyle G, Gazzard B. Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs. 1996;51(5):701–12.

Article  CAS  PubMed  Google Scholar 

Moyle GJ, Youle M, Higgs C, Monaghan J, Prince W, Chapman S, Clendeninn N, Nelson MR. Safety, pharmacokinetics, and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: results of a phase I/II trial and extended follow-up in patients infected with human immunodeficiency virus. J Clin Pharmacol. 1998;38(8):736–43.

Article  CAS  PubMed  Google Scholar 

Johnson M, Nieto-Cisneros L, Horban A, Arasteh K, Gonzalez-Garcia J, Artigas JG, Clotet B, Danise A, Landman R, Proll S, et al. Comparison of gastrointestinal tolerability and patient preference for treatment with the 625 mg and 250 mg nelfinavir tablet formulations. HIV Med. 2005;6(2):107–13.

Article  CAS  PubMed  Google Scholar 

Gantt S, Casper C, Ambinder RF. Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and prevention. Curr Opin Oncol. 2013;25(5):495–502.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gantt S, Carlsson J, Ikoma M, Gachelet E, Gray M, Geballe AP, Corey L, Casper C, Lagunoff M, Vieira J. The HIV protease inhibitor nelfinavir inhibits Kaposi’s sarcoma-associated herpesvirus replication in vitro. Antimicrob Agents Chemother. 2011;55(6):2696–703.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gantt S, Gachelet E, Carlsson J, Barcy S, Casper C, Lagunoff M. Nelfinavir impairs glycosylation of herpes simplex virus 1 envelope proteins and blocks virus maturation. Adv Virol 2015, 2015:687162.

Kalu NN, Desai PJ, Shirley CM, Gibson W, Dennis PA, Ambinder RF. Nelfinavir inhibits maturation and export of herpes simplex virus 1. J Virol. 2014;88(10):5455–61.

Article  PubMed  PubMed Central  Google Scholar 

De Gassart A, Bujisic B, Zaffalon L, Decosterd LA, Di Micco A, Frera G, Tallant R, Martinon F. An inhibitor of HIV-1 protease modulates constitutive eIF2alpha dephosphorylation to trigger a specific integrated stress response. Proc Natl Acad Sci U S A. 2016;113(2):E117–126.

Article  PubMed  Google Scholar 

Gupta AK, Li B, Cerniglia GJ, Ahmed MS, Hahn SM, Maity A. The HIV protease inhibitor nelfinavir downregulates akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response. Neoplasia. 2007;9(4):271–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guan M, Fousek K, Chow WA. Nelfinavir inhibits regulated intramembrane proteolysis of sterol regulatory element binding protein-1 and activating transcription factor 6 in castration-resistant prostate cancer. FEBS J. 2012;279(13):2399–411.

Article  CAS  PubMed  Google Scholar 

Gills JJ, Lopiccolo J, Tsurutani J, Shoemaker RH, Best CJ, Abu-Asab MS, Borojerdi J, Warfel NA, Gardner ER, Danish M, et al. Nelfinavir, a lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res. 2007;13(17):5183–94.

Article  CAS  PubMed  Google Scholar 

Mahameed M, Boukeileh S, Obiedat A, Darawshi O, Dipta P, Rimon A, McLennan G, Fassler R, Reichmann D, Karni R, et al. Pharmacological induction of selective endoplasmic reticulum retention as a strategy for cancer therapy. Nat Commun. 2020;11(1):1304.

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Gantt S, Cattamanchi A, Krantz E, Magaret A, Selke S, Kuntz SR, Huang ML, Corey L, Wald A, Casper C. Reduced human herpesvirus-8 oropharyngeal shedding associated with protease inhibitor-based antiretroviral therapy. J Clin Virol. 2014;60(2):127–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vieira J, O’Hearn PM. Use of the red fluorescent protein as a marker of Kaposi’s sarcoma-associated herpesvirus lytic gene expression. Virology. 2004;325(2):225–40.

Article  CAS  PubMed  Google Scholar 

Desai P, DeLuca NA, Person S. Herpes simplex virus type 1 VP26 is not essential for replication in cell culture but influences production of infectious virus in the nervous system of infected mice. Virology. 1998;247(1):115–24.

Article  CAS  PubMed  Google Scholar 

Myoung J, Ganem D. Generation of a doxycycline-inducible KSHV producer cell line of endothelial origin: maintenance of tight latency with efficient reactivation upon induction. J Virol Methods. 2011;174(1–2):12–21.

Article  PubMed  PubMed Central  Google Scholar 

Cannon JS, Ciufo D, Hawkins AL, Griffin CA, Borowitz MJ, Hayward GS, Ambinder RF. A new primary effusion lymphoma-derived cell line yields a highly infectious Kaposi’s sarcoma herpesvirus-containing supernatant. J Virol. 2000;74(21):10187–93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee J, Stone J, Desai P, Kosowicz JG, Liu JO, Ambinder RF. Arsenicals, the Integrated Stress Response, and Epstein-Barr Virus Lytic Gene expression. Viruses 2021, 13(5).

Lee J, Kosowicz JG, Hayward SD, Desai P, Stone J, Lee JM, Liu JO, Ambinder RF. Pharmacologic activation of Lytic Epstein-Barr Virus Gene expression without Virion Production. J Virol 2019, 93(20).

Luitweiler EM, Henson BW, Pryce EN, Patel V, Coombs G, McCaffery JM, Desai PJ. Interactions of the Kaposi’s sarcoma-associated herpesvirus nuclear egress complex: ORF69 is a potent factor for remodeling cellular membranes. J Virol. 2013;87(7):3915–29.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ward PL, Ogle WO, Roizman B. Assemblons: nuclear structures defined by aggregation of immature capsids and some tegument proteins of herpes simplex virus 1. J Virol. 1996;70(7):4623–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu D, Wang V, Yang M, Abdullah S, Davis DA, Uldrick TS, Polizzotto MN, Veeranna RP, Pittaluga S, Tosato G, et al. Induction of Kaposi’s Sarcoma-Associated Herpesvirus-encoded viral Interleukin-6 by X-Box binding protein 1. J Virol. 2016;90(1):368–78.

Article  CAS  PubMed  Google Scholar 

Johnson CE, Hunt DK, Wiltshire M, Herbert TP, Sampson JR, Errington RJ, Davies DM, Tee AR. Endoplasmic reticulum stress and cell death in mTORC1-overactive cells is induced by nelfinavir and enhanced by chloroquine. Mol Oncol. 2015;9(3):675–88.

Article  CAS  PubMed  Google Scholar 

Obiedat A, Charpak-Amikam Y, Tai-Schmiedel J, Seidel E, Mahameed M, Avril T, Stern-Ginossar N, Springuel L, Bolsee J, Gilham DE, et al. The integrated stress response promotes B7H6 expression. J Mol Med (Berl). 2020;98(1):135–48.

Article  CAS  PubMed  Google Scholar 

Okoye ME, Sexton GL, Huang E, McCaffery JM, Desai P. Functional analysis of the triplex proteins (VP19C and VP23) of herpes simplex virus type 1. J Virol. 2006;80(2):929–40.